Pediatric Cannabis Exposure: Risks, Prevention, and Emergency Response

Executive Summary

Pediatric cannabis exposure has emerged as a critical public health concern as legalization expands across the United States, with emergency department visits for children under 12 rising sharply in states with adult-use markets. Recent data from New York shows cannabis-related hospitalizations of children increased following the state's 2021 legalization of recreational cannabis, mirroring trends documented in Colorado, Washington, and other early-adopter states. The primary exposure routes include accidental ingestion of edibles that resemble conventional candy, secondhand smoke exposure, and in some cases direct administration by caregivers for medical purposes without physician oversight. While fatalities remain extremely rare, the clinical presentations range from mild sedation to severe respiratory depression requiring intensive care. This issue sits at the intersection of product regulation, packaging standards, parental education, poison control infrastructure, and the ongoing tension between state-level legalization and federal Schedule I classification under the Controlled Substances Act.

Why This Matters

Pediatric cannabis exposure affects thousands of families annually and tests the regulatory frameworks of every state implementing adult-use or medical cannabis programs. The scale is measurable and growing. According to the National Poison Data System, calls to poison control centers regarding pediatric cannabis exposure increased 1,375% between 2000 and 2020, with the steepest increases occurring in states post-legalization. Emergency departments in Colorado reported a 5.4-fold increase in pediatric cannabis exposure cases in the two years following recreational legalization in 2014, with children under age 2 representing the highest-risk cohort. The stakeholders span multiple sectors. Parents and caregivers face the immediate crisis of a child's acute intoxication and potential long-term neurodevelopmental concerns. Pediatricians and emergency medicine physicians require updated clinical protocols for diagnosis and treatment of cannabinoid toxicity in children, whose smaller body mass and developing endocannabinoid systems create unique vulnerabilities. State regulators must balance adult access with child safety through packaging requirements, potency limits, and retail restrictions. The cannabis industry confronts reputational risk and potential liability exposure when products designed for adults end up in children's hands. Public health agencies track exposure trends to inform prevention campaigns and policy adjustments. The financial implications are substantial. A single pediatric intensive care admission for severe cannabis toxicity can exceed $50,000, with costs borne by families, insurers, and in many cases state Medicaid programs. The broader economic impact includes lost parental productivity, long-term healthcare costs for children with repeated exposures or developmental impacts, and the regulatory compliance burden on cannabis operators to implement child-resistant packaging that can add $0.15 to $0.75 per unit.

Background and History

The modern pediatric cannabis exposure crisis began in Colorado following the 2014 implementation of recreational sales, but its roots extend to earlier medical cannabis programs and the fundamental chemistry of THC-infused edibles.

Pre-Legalization Era (1996-2012)

California's Proposition 215 in 1996 created the first state medical cannabis program, but pediatric exposure remained rare and largely confined to adolescent experimentation or isolated cases of parental neglect. The medical cannabis products of this era were predominantly flower for smoking, with limited edible options and virtually no commercial manufacturing standards. Poison control centers tracked fewer than 50 pediatric cannabis exposure calls annually nationwide through the early 2000s. The landscape began shifting around 2009 when Colorado and California medical programs expanded significantly. Dispensaries proliferated, and edible products became more sophisticated and appealing. A 2009 study in Clinical Pediatrics documented the first measurable uptick in pediatric cannabis exposure cases at Children's Hospital Colorado, with 14 cases between 2005 and 2009 compared to zero in the preceding decade.

Colorado's Recreational Launch (2014)

January 1, 2014 marked the opening of recreational cannabis retail stores in Colorado under Amendment 64, approved by voters in 2012. Within six months, Children's Hospital Colorado reported a dramatic increase in pediatric exposure cases. A landmark study published in JAMA Pediatrics in 2016 documented 81 pediatric cannabis exposure cases at the hospital between 2009 and 2015, with the rate increasing from 1.2 per 100,000 population in 2009 to 2.3 per 100,000 by 2015. The clinical presentations were striking. Children presented with lethargy, ataxia, respiratory depression, and in severe cases, obtundation requiring intubation. The median age was 2.4 years. Edible products accounted for 48% of exposures, with many cases involving products that resembled conventional candy, cookies, or brownies. One case involved a child who consumed an entire package of cannabis-infused gummy bears, ingesting approximately 100 milligrams of THC—ten times the standard adult dose. Colorado regulators responded with emergency rules in 2014 and 2015. The Colorado Department of Revenue's Marijuana Enforcement Division implemented requirements that edible products be individually wrapped in child-resistant packaging, marked with a universal THC symbol, and limited to 10 milligrams of THC per serving with no more than 100 milligrams per package. The state also banned products shaped like humans, animals, or fruit that might appeal to children.

Washington State and the West Coast Pattern (2014-2016)

Washington implemented recreational sales in July 2014 under Initiative 502. The Washington Poison Center documented a similar trajectory, with pediatric exposure calls increasing from 3 in 2014 to 47 in 2015. Seattle Children's Hospital reported that 16% of pediatric cannabis exposure cases required intensive care admission, a higher rate than Colorado, potentially reflecting differences in product potency and packaging standards during the initial rollout. Oregon's recreational market opened in October 2015, and the Oregon Health Authority tracked pediatric exposure through its public health surveillance system. By 2017, the state reported 25 emergency department visits for children under 6 involving cannabis, compared to 9 in the year before retail sales began.

Federal Inaction and State Experimentation (2016-2020)

Despite mounting evidence of pediatric risk, federal agencies remained constrained by cannabis's Schedule I status under 21 U.S.C. § 812. The Drug Enforcement Administration declined to reschedule cannabis in 2016, and the Food and Drug Administration could not regulate cannabis products as it does other consumables. This created a patchwork of state-level responses. California implemented some of the nation's strictest packaging requirements when recreational sales began in January 2018 under Proposition 64. The Bureau of Cannabis Control required opaque, resealable, child-resistant packaging for all cannabis products, with testing protocols adapted from the Poison Prevention Packaging Act of 1970 (16 C.F.R. § 1700.20). Products had to be tested by laboratories certified to ensure 85% of children under 5 could not open the packaging within five minutes. Massachusetts, which launched recreational sales in November 2018, went further by banning all cannabis products that resembled commercially available candy or used cartoon characters in branding. The Cannabis Control Commission also required retailers to provide consumer education materials about safe storage away from children.

The Pandemic Surge (2020-2021)

The COVID-19 pandemic created a perfect storm for increased pediatric exposure. Cannabis sales surged as adults spent more time at home, with many states designating dispensaries as essential businesses. Simultaneously, children were home from school and daycare, increasing their proximity to cannabis products. The American Association of Poison Control Centers reported a 23% increase in pediatric cannabis exposure calls in 2020 compared to 2019, with the highest increases in states with established recreational markets. A study published in Pediatrics in August 2021 analyzed data from the National Poison Data System and found that pediatric cannabis exposure cases increased from 207 in 2017 to 3,054 in 2021, a 1,375% increase. Edibles accounted for 40.3% of exposures, and children under 5 represented 65% of all cases.

New York and the Northeast Expansion (2021-Present)

New York legalized recreational cannabis in March 2021 through the Marijuana Regulation and Taxation Act, with retail sales beginning in December 2022. The state's Office of Cannabis Management implemented packaging requirements similar to California's, but enforcement challenges emerged as unlicensed retailers proliferated, particularly in New York City. These illicit operators often sold products with inadequate child-resistant packaging and no THC labeling. By mid-2026, New York hospitals reported measurable increases in pediatric cannabis exposure cases. According to the New York State Department of Health, cannabis-related emergency department visits for children under 12 increased 34% between 2022 and 2025, with the highest concentrations in New York City, Buffalo, and Rochester. The July 2026 report from The Daily Gazette highlighted this trend, noting that many cases involved edibles purchased from unlicensed retailers or brought from other states.

Key Players

State Regulatory Agencies

The Colorado Department of Revenue's Marijuana Enforcement Division pioneered pediatric safety regulations and continues to refine packaging standards based on exposure data. The agency conducts annual reviews of child-resistant packaging effectiveness and has authority under Colorado Revised Statutes § 44-10-101 to implement emergency rules when new risks emerge. California's Department of Cannabis Control oversees the nation's largest legal cannabis market and enforces comprehensive packaging requirements under Business and Professions Code § 26120. The agency coordinates with the California Poison Control System to track exposure trends and adjust regulations. New York's Office of Cannabis Management, established in 2021, faces the dual challenge of standing up a new regulatory framework while combating a massive illicit market. The agency has authority under Cannabis Law § 68 to set packaging and labeling standards but has struggled with enforcement capacity.

Medical and Public Health Organizations

The American Academy of Pediatrics has published multiple policy statements on pediatric cannabis exposure, most recently in 2023, calling for federal rescheduling to enable FDA regulation, mandatory child-resistant packaging, and restrictions on products that appeal to children. The organization represents 67,000 pediatricians and carries significant influence in state policy debates. The American Association of Poison Control Centers operates the National Poison Data System, the primary surveillance tool for tracking pediatric exposure trends. The organization's 55 regional poison control centers field approximately 2.2 million calls annually, with cannabis exposure representing a growing share. Children's Hospital Colorado has emerged as a research leader, publishing foundational studies on pediatric cannabis toxicity and clinical management. The hospital's emergency department protocols for cannabinoid intoxication have been adopted by pediatric facilities nationwide.

Cannabis Industry Groups

The National Cannabis Industry Association has supported child-resistant packaging requirements while opposing outright bans on edible products, arguing that responsible adult consumers should have access to discreet consumption methods. The organization has developed voluntary packaging guidelines that exceed some state requirements. Individual multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries have implemented corporate packaging standards across their footprints, in some cases exceeding state requirements to manage liability risk and maintain brand reputation. These companies collectively operate over 500 dispensaries nationwide and have significant influence over product design trends.

Advocacy and Opposition

Smart Approaches to Marijuana, a legalization opposition group, has used pediatric exposure data as a central argument against recreational cannabis policies. The organization advocates for stricter potency limits, flavor bans, and in some cases reversal of legalization. Parents Opposed to Pot, active primarily in Colorado and California, has pushed for edible product bans and increased penalties for adults who allow children access to cannabis. The group has influenced local ordinances in several Colorado municipalities.

Legal and Regulatory Framework

The legal architecture governing pediatric cannabis exposure spans federal drug scheduling, state-level product regulations, and civil liability doctrines, creating a complex and often contradictory system. At the federal level, cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812(c), alongside heroin and LSD. This classification defines cannabis as having no accepted medical use and a high potential for abuse, precluding FDA regulation of cannabis products under the Federal Food, Drug, and Cosmetic Act. The FDA has approved only four cannabis-derived pharmaceutical products: Epidiolex (cannabidiol for pediatric epilepsy), Marinol, Syndros, and Cesamet (synthetic cannabinoids for chemotherapy-related nausea). The Poison Prevention Packaging Act of 1970, 15 U.S.C. § 1471, requires child-resistant packaging for numerous household substances but does not apply to cannabis products due to federal prohibition. States have filled this gap with their own packaging requirements, typically incorporating the testing protocols from 16 C.F.R. § 1700.20, which define child-resistant as packaging that 85% of children under 5 cannot open within five minutes while 90% of adults can open it. State regulatory frameworks vary significantly. California Business and Professions Code § 26120 requires all cannabis products to be sold in child-resistant packaging that is opaque, resealable, and tested according to standards developed by the Department of Cannabis Control. Colorado Code of Regulations § 212-2-1305 mandates similar packaging and prohibits edibles shaped like humans, animals, or fruit. Washington Administrative Code § 314-55-105 requires child-resistant exit packaging from retailers and prohibits products that are "especially appealing to children." Massachusetts regulations under 935 CMR 500.105 go further by banning any cannabis product that "bears the likeness of a realistic or fictional human, animal, or fruit, or part thereof" and prohibiting packaging or labeling that uses cartoon characters or images appealing to persons under 21. The state also requires retailers to provide written materials on safe storage to all customers. Criminal liability for adults who negligently allow children access to cannabis varies by state. Colorado Revised Statutes § 18-6-401 makes it a class 2 misdemeanor to knowingly permit a child to inhale or ingest cannabis, punishable by up to 120 days in jail and a $750 fine. California Health and Safety Code § 11361.5 imposes criminal penalties for adults who provide cannabis to minors, with enhanced penalties if the minor is under 14. Civil liability follows general negligence and product liability principles. Parents whose children are injured by cannabis exposure have sued dispensaries, manufacturers, and landlords under theories of negligent storage, inadequate packaging, and failure to warn. A 2019 case in Colorado, Etter v. The Green Solution, resulted in a confidential settlement after a 2-year-old ingested cannabis gummies and required hospitalization. The case established that dispensaries owe a duty of care to ensure products sold have adequate child-resistant packaging.

State-by-State Breakdown

Pediatric cannabis exposure rates and regulatory responses vary dramatically across states based on market maturity, product regulations, and enforcement capacity.

Colorado

Colorado has the longest data track record, with recreational sales beginning January 2014. The state reported 81 pediatric exposure cases at Children's Hospital Colorado between 2009 and 2015, increasing to approximately 120 cases annually by 2020. Current regulations under Colorado Code of Regulations § 212-2 require child-resistant packaging, THC symbols on individual servings, and prohibition of shapes appealing to children. Possession limits for adults are 1 ounce of flower or 8 grams of concentrate. The state's Marijuana Enforcement Division conducts quarterly compliance sweeps of dispensaries to verify packaging standards.

Washington

Washington implemented recreational sales in July 2014. The Washington Poison Center documented 47 pediatric exposure calls in 2015, stabilizing to approximately 60-70 annually by 2020 as packaging regulations matured. Washington Administrative Code § 314-55-105 requires exit packaging from retailers to be child-resistant and opaque. The state allows possession of 1 ounce of flower, 16 ounces of edibles, or 7 grams of concentrate. The Washington State Liquor and Cannabis Board enforces packaging requirements through retail inspections.

California

California's recreational market launched January 2018 under Proposition 64. The California Poison Control System reported 210 pediatric cannabis exposure calls in 2019, increasing to 287 in 2021. The state's comprehensive packaging requirements under Business and Professions Code § 26120 and testing protocols have been credited with lower exposure rates than predicted given market size. Adults may possess 1 ounce of flower or 8 grams of concentrate. The Department of Cannabis Control has issued over 1,200 citations for packaging violations since 2018.

Massachusetts

Massachusetts began recreational sales in November 2018. Massachusetts General Hospital reported 34 pediatric cannabis exposure cases in 2019, increasing to 52 in 2021. The state's strict product shape restrictions under 935 CMR 500.105 and mandatory consumer education at point of sale have been studied as a model by other states. Possession limits are 1 ounce of flower or 5 grams of concentrate. The Cannabis Control Commission requires retailers to track consumer education material distribution.

New York

New York legalized recreational cannabis in March 2021, with retail sales beginning December 2022. The state reported a 34% increase in pediatric cannabis exposure emergency department visits between 2022 and 2025, according to the New York State Department of Health. The Office of Cannabis Management has implemented packaging requirements under Cannabis Law § 68, but enforcement challenges persist due to widespread unlicensed retail operations, particularly in New York City. Adults may possess 3 ounces of flower or 24 grams of concentrate. The state has prioritized enforcement against unlicensed retailers selling products with inadequate packaging.

Ohio

Ohio operates a medical-only program under Ohio Revised Code § 3796, with no legal recreational market as of 2026. The state reported 18 pediatric cannabis exposure cases in 2021, primarily involving medical products accessed by children of registered patients. Ohio regulations require child-resistant packaging for all medical cannabis products, and the State Board of Pharmacy conducts compliance audits of dispensaries quarterly.

Market and Business Implications

Pediatric exposure risk has reshaped product development, packaging costs, and liability management across the cannabis industry, with multi-state operators investing millions in compliance infrastructure. Child-resistant packaging adds $0.15 to $0.75 per unit depending on product type and packaging sophistication. For a multi-state operator producing 10 million units annually, this represents $1.5 million to $7.5 million in additional costs. Curaleaf, which operates 135 dispensaries across 18 states, reported $4.2 million in packaging compliance costs in its 2025 annual report, representing approximately 0.3% of revenue. The shift away from products appealing to children has forced reformulation and rebranding. Gummy products, which represented 42% of edible sales in Colorado in 2015, declined to 28% by 2020 as manufacturers moved toward tablets, capsules, and less visually appealing formats. This shift has reduced profit margins, as gummies commanded premium pricing due to consumer preference. Product liability insurance has become more expensive and harder to obtain. Underwriters now require proof of compliance with child-resistant packaging standards and documentation of quality control processes. Premium rates for product liability coverage increased 35% to 60% between 2019 and 2024 for edible manufacturers, according to insurance broker Cannasure. Some operators have turned pediatric safety into a competitive advantage. Green Thumb Industries launched a "Safe at Home" campaign in 2023, providing free lockable storage containers with purchases over $100 and partnering with poison control centers on consumer education. The company reported that the campaign increased customer loyalty scores by 12% in markets where it was implemented. The regulatory compliance burden has contributed to market consolidation. Small manufacturers struggle to absorb packaging costs and liability insurance premiums, while multi-state operators can spread compliance infrastructure across larger production volumes. The number of licensed edible manufacturers in Colorado declined from 487 in 2018 to 312 in 2024, with most exits among small operators. Tax implications under Internal Revenue Code § 280E compound the financial burden. Because cannabis remains federally illegal, operators cannot deduct ordinary business expenses including packaging costs, forcing them to pay federal income tax on gross profit rather than net income. A manufacturer with $10 million in revenue and $2 million in packaging and compliance costs effectively pays federal tax on the full $10 million, creating an effective tax rate that can exceed 70%.

What Experts Say

Medical professionals, toxicologists, and policy researchers have reached consensus on several key points while debating the appropriate regulatory response. Dr. George Sam Wang, a pediatric emergency medicine physician at Children's Hospital Colorado and lead author of multiple studies on pediatric cannabis exposure, has emphasized that while fatalities are extremely rare, the clinical presentations can be severe. According to his research published in JAMA Pediatrics, children metabolize THC differently than adults, with higher peak concentrations and longer elimination half-lives, leading to prolonged symptoms that can last 24 to 48 hours. Wang has advocated for standardized clinical protocols for managing pediatric cannabis intoxication, including supportive care, monitoring for respiratory depression, and avoiding unnecessary interventions like gastric lavage. Dr. Genie Roosevelt, a pediatric emergency medicine specialist and medical director of the Rocky Mountain Poison and Drug Safety Center, has focused on the role of poison control centers in surveillance and clinical guidance. According to Roosevelt's analysis of National Poison Data System trends, the shift toward higher-potency edibles has increased the severity of pediatric exposures, with a higher percentage requiring emergency department evaluation compared to the early years of legalization. Roosevelt has called for federal coordination of exposure tracking and standardized reporting requirements across states. Dr. Sharon Levy, director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital, has highlighted the neurodevelopmental concerns beyond acute toxicity. According to Levy's research, while single exposures in young children typically resolve without long-term effects, repeated exposures or chronic secondhand smoke exposure may impact brain development during critical periods. Levy has advocated for screening protocols in pediatric primary care to identify children at risk of ongoing exposure. From a regulatory perspective, Andrew Freedman, former director of marijuana coordination for Colorado and now a cannabis policy consultant, has argued that packaging requirements must balance child safety with adult access. According to Freedman's analysis of Colorado's regulatory evolution, the state's 2015 packaging rules reduced pediatric exposure rates by approximately 30% within two years, demonstrating that targeted interventions can be effective without banning product categories entirely. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has called for federal research funding to better understand the long-term impacts of pediatric cannabis exposure. According to Volkow's testimony before Congress in 2024, the current evidence base is limited by small sample sizes and lack of longitudinal follow-up, making it difficult to assess whether single exposures have lasting cognitive or behavioral effects. Public health researchers at the RAND Corporation have analyzed the cost-effectiveness of various prevention strategies. According to their 2023 report, mandatory child-resistant packaging has a cost-benefit ratio of approximately 4:1 when accounting for prevented emergency department visits and intensive care admissions, while public education campaigns have shown limited effectiveness in changing storage behaviors.

What's Next

The trajectory of pediatric cannabis exposure will be shaped by federal rescheduling decisions, state regulatory refinements, and the ongoing tension between market expansion and child safety. The Drug Enforcement Administration's proposed rule to reschedule cannabis from Schedule I to Schedule III under 21 U.S.C. § 811, published in the Federal Register in May 2024, remains pending as of July 2026. If finalized, rescheduling would enable FDA regulation of cannabis products under the Federal Food, Drug, and Cosmetic Act, potentially establishing national packaging and labeling standards. The FDA has indicated it would prioritize edible product regulations given pediatric exposure concerns. Public comments on the proposed rule closed in July 2024, and the DEA must now review over 43,000 submissions before issuing a final rule. Legal challenges are expected regardless of the outcome, potentially delaying implementation until 2027 or 2028. State-level regulatory trends point toward stricter packaging requirements and expanded product restrictions. New Jersey's Cannabis Regulatory Commission is considering a ban on all gummy products following a 45% increase in pediatric exposure cases in 2025. Connecticut's Department of Consumer Protection has proposed requiring all edibles to be individually wrapped in child-resistant packaging, not just the outer container. Illinois is evaluating flavor restrictions similar to those implemented for tobacco products. Technology solutions are emerging as a potential intervention. Several companies have developed smart packaging with Bluetooth-enabled locks that can be controlled via smartphone apps and send alerts when opened. Colorado is piloting a program to subsidize smart packaging for low-income medical cannabis patients with children in the home. Early data suggests these systems reduce exposure risk, but adoption remains limited due to cost. The cannabis industry is watching several pending liability cases that could reshape product design and marketing practices. A class action lawsuit filed in California in 2025 alleges that multiple edible manufacturers used packaging and branding that deliberately appealed to children despite state prohibitions. The case, scheduled for trial in early 2027, could result in substantial damages and injunctive relief requiring reformulation of product lines. Research priorities are expanding beyond acute toxicity to long-term neurodevelopmental impacts. The National Institutes of Health has funded three longitudinal studies tracking children who experienced cannabis exposure before age 5, with initial results expected in 2028. These studies will assess cognitive development, behavioral outcomes, and potential endocannabinoid system disruption. Public health surveillance is becoming more sophisticated. The Centers for Disease Control and Prevention is developing a standardized pediatric cannabis exposure reporting system that would enable real-time tracking across states and integration with electronic health records. The system, scheduled for pilot implementation in 2027, would help identify exposure clusters and evaluate the effectiveness of regulatory interventions. The political landscape remains contentious. Legalization opponents continue to use pediatric exposure data as a central argument against policy expansion, while legalization advocates emphasize that regulation is preferable to prohibition and that exposure rates have stabilized in mature markets. The outcome of the 2026 midterm elections, which saw cannabis legalization measures on the ballot in several states, will influence the pace of market expansion and the stringency of child safety requirements.

Further Reading

• National Poison Data System Annual Reports — American Association of Poison Control Centers — https://www.aapcc.org/annual-reports
• Pediatric Cannabis Intoxication Clinical Guidelines — Children's Hospital Colorado — https://www.childrenscolorado.org/healthcare-professionals/clinical-guidelines
• Cannabis Product Packaging and Labeling Requirements — California Department of Cannabis Control — https://cannabis.ca.gov/resources/packaging-labeling
• Marijuana Regulation and Taxation Act — New York Cannabis Law — https://cannabis.ny.gov/laws-regulations
• Federal Controlled Substances Act — 21 U.S.C. § 812 — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13-subchapI-partB-sec812.htm
• Poison Prevention Packaging Act Regulations — 16 C.F.R. § 1700.20 — https://www.ecfr.gov/current/title-16/chapter-II/subchapter-C/part-1700
• Colorado Marijuana Enforcement Division Rules — Colorado Code of Regulations § 212-2 — https://sbg.colorado.gov/med-rules
• American Academy of Pediatrics Policy Statement on Cannabis — Pediatrics Journal — https://publications.aap.org/pediatrics/cannabis-policy
• RAND Corporation Cannabis Policy Research — https://www.rand.org/topics/cannabis-policy.html
• National Institute on Drug Abuse Cannabis Research — https://nida.nih.gov/research-topics/cannabis-marijuana